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Abstract
Purpose/Objective: This is a prospective comparison of weekly cisplatin to weekly paclitaxel as concurrent
chemotherapy with standard radiotherapy for locally advanced cervical carcinoma.
Materials/Methods: Between May 2000 and May 2004, 31 women with FIGO stage IB2-IVA cervical cancer or with
postsurgical pelvic recurrence were enrolled into this phase II study and randomized to receive on a weekly basis
either 40 mg/m
2 Cisplatin (group I; 16 patients) or 50 mg/m
2 paclitaxel (group II; 15 patients) concurrently with
radiotherapy. Median total dose to point A was 74 Gy (range: 66-92 Gy) for group I and 66 Gy (range: 40-98 Gy) for
group II. Median follow-up time was 46 months.
Results: Patient and tumor characteristics were similar in both groups. The mean number of chemotherapy cycles
was also comparable with 87% and 80% of patients receiving at least 4 doses in groups I and II, respectively. Seven
patients (44%) of group I and 8 patients (53%) of group II developed tumor recurrence. The Median Survival time
was not reached for Group I and 53 months for group II. The proportion of patients surviving at 2 and 5 years was
78% and 54% for group I and 73% and 43% for group II respectively.
Conclusions: This small prospective study shows that weekly paclitaxel does not provide any clinical advantage
over weekly cisplatin for concurrent chemoradiation for advanced carcinoma of the cervix.
Introduction
In many developing countries, cervical cancer remains a
major public health problem with high overall incidence
and higher frequency of advanced stage at diagnosis.
Radiation therapy remains the main treatment modality
for patients with advanced cervical cancer the results of
which depend on disease stage, tumor volume, presence
of involved lymph nodes, delivered radiation dose, treat-
ment duration, hemoglobin level, and the optimal use of
intracavitary brachytherapy [1-5]. Nodal involvement,
particularly of paraaortic nodes, was reported to be the
most important adverse prognostic factor, reducing sur-
vival by one-half. A series of controlled randomized
studies have shown that the outcome of these patients
can be improved by the use of concurrent chemora-
diotherapy (CTRT) protocols [6-16]. Based on these
trials, the National Cancer Institute issued a clinical
alert stating that “strong consideration should be given
to the incorporation of concurrent cisplatin-based che-
motherapy with radiation in women who require radia-
tion therapy for cervical cancer” [17,18]. At present, the
integration of radiosensitizing cisplatin-based che-
motherapy with local treatment is considered the
accepted standard in the management of high-risk
patients with carcinoma of the cervix [19-21].
Despite the use of concurrent CTRT, many patients
continue to fail in the pelvis (20-25%) and at distant
sites (10-20%), [6,16,21-23]. In addition, the use of cis-
platin-based chemotherapy concurrently with RT has
not been invariably effective. A study by the National
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single agent cisplatin has shown no clinical benefit
from this schedule [24]. These facts have stimulated
interests in exploring other concurrent combinations
with potentially more clinical effect. Paclitaxel is a tax-
ane chemotherapy drug that was found to have signifi-
cant activity in solid tumors especially epithelial
ovarian cancer, lung, and breast cancer [25-28]. Precli-
nical studies have shown a radiosensitizing effect of
paclitaxel in human cervical cancer cell lines [29,30]. It
was also shown that this drug exerts a preferential
cytotoxic activity in human cervical cancer cells with
low Raf-1 kinase activity which makes it desirable to
be used in conjunction with radiotherapy [30]. The
clinical feasibility of concurrent RT and paclitaxel was
tested in phase I trials and a maximum tolerated dose
(MTD) of 50 mg/m2 per week concurrently with radia-
tion therapy was established [31,32]. In addition, the
clinical efficacy of paclitaxel has been tested in phase
II and III studies for metastatic and recurrent cervical
cancer with objective response rates ranging between
36 and 47% [33-35].
In this study, we examine the tumor response, treat-
ment toxicity, and outcome of patients with locally
advanced cervical cancer treated by concurrent radiation
therapy and chemotherapy using either weekly Cisplatin
or weekly paclitaxel.
Methods and materials
Patients
Patients presenting to the American University of Beirut
Medical Center, with advanced carcinoma of the cervix,
stages IB2-IVA according to the Federation Internatio-
nale de Gynecologie Obstetrique (FIGO) staging system,
or with measurable central pelvic recurrence, were eligi-
ble to enroll in this phase II randomized prospective
study. Inclusion criteria also included: age <80 years;
Gynecologic Oncology Group (GOG) performance sta-
tus of 0-3; adequate hematological and biochemical pro-
file with absolute neutrophil count >1.5 × 10
9/L,
platelets >100 × 10
9/L; creatinine <1.5, liver enzymes
(AST and ALT) <3 × normal, and bilirubin <1.25 nor-
mal. Patients with evidence of enlarged paraaortic
lymphnodes, history of peripheral neuropathy, prior
radiotherapy, prior chemotherapy (neoadjuvant), hyper-
sensitivity to cisplatin or paclitaxel, or other synchro-
nous malignancies were considered not eligible.
Treatment was started within 48 hours of randomiza-
tion. Between May 2000 and May 2004, 31 women were
enrolled and randomized to receive on a weekly basis
either 40 mg/m
2 Cisplatin (group I; 16 patients) or 50
mg/m
2 paclitaxel (group II; 15 patients) concurrently
with radiotherapy.
Chemotherapy
Patients were randomized into two groups: group 1 trea-
ted with weekly cisplatin and group 2 treated with
weekly paclitaxel. Group I patients received weekly
cisplatin 40 mg/m
2 given intravenously in 200 cc of D5-
NSS over one hour. Premedication consisted of dexa-
methasone 8 mg IV, and a 5HT3-receptor antagonist as
antiemetic with hydration for two hours before and after
chemotherapy with D5-NSS at 150 cc/hour. Group II
patients were treated with weekly paclitaxel 50 mg/m
2
given intravenously in 500 cc of D5W in a glass con-
tainer over three hours. Premedication consisted of dex-
amethasone 8 mg IV, Benadryl 25 mg IV, Ranitidine 50
mg IV, and a 5HT3-receptor antagonist as antiemetic.
Planned treatment was for an average of 5-6 cycles to
coincide with the duration of external beam radiation
and continued during brachytherapy.
Radiation therapy
Radiation treatment consisted of external beam radiation
to 40 Gy in 20 fractions using 15 MV photons and an
anteroposterior pelvic field arrangement. This was fol-
lowed by low-dose, or high-dose rate uterovaginal bra-
chytherapy (UVB). Patients treated before 2001 received
low-dose Cesium brachytherapy, but after 2001, eligible
patients were treated with high-dose rate Iridium bra-
chytherapy. Patients who had parametrial involvement
also received a parametrial boost to the affected side.
Median total dose to point A was 74 Gy (range: 66-92
G y )f o rg r o u pIa n d6 6G y( r a n g e :4 0 - 9 8G y )f o rg r o u p
II. Patients who had poor vaginal anatomy, or had prior
hysterectomy were treated with an external radiation
boost instead of uterovaginal brachytherapy to a median
total central pelvic dose of 60.4 Gy (range: 60-66 Gy).
The first HDR brachytherapy application was inserted
no later than 7 days after completion of pelvic radiation.
Baseline evaluation and follow-up
Tumor size was assessed clinically by two different
examiners prior to, and following treatment. Initial
work-up included a complete blood and platelet counts
(CBC), creatinine (Cr), liver function tests (SGPT, Alk.
P., Gamma GT). Computerized tomography (CT) scan-
ning of the abdomen and pelvis, and chest x-ray (CXR).
During treatment, patients had weekly CBC, Cr., and
liver function tests. Patients who developed any allergic
reactions during cisplatin and paclitaxel, were subse-
quently pretreated with dexamethasone 8 mg orally
every 8 hours for three doses prior to the admission for
chemotherapy. After completing therapy, patients had a
repeat baseline examination and CT scan of the abdo-
men and pelvis. Later follow-up evaluation consisted of
repeat pelvic examinations every 3 months for the first
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sion or deaths. Pap smears, CXR, and CT scans of the
abdomen and pelvis were obtained every 6 months.
Endpoints ans statistical anlysis
The primary endpoints were treatment response, overall
survival, and time to relapse. Time to relapse was
defined from the date of entry into the study to the date
of recurrence. Patients with progressive disease who
never achieved complete response, were censored for
relapse at the end of radiation therapy, which is approxi-
mately 2 months and half from the date of entry. Dis-
ease free survival was defined as alive with no evidence
of disease at the time of last follow-up or dead without
evidence of disease. Survival was calculated from the
date of entry to the date of death or last follow-up.
Cumulative survival rates was estimated by the Kaplan-
Meier method and compared using the Logrank tests.
Chi-square and the student’ t-test were used for com-
parative analyses. Statistical significance was defined as
p < 0.05. Data were analyzed using a SPSS program ver-
sion 16.0. Patient lost to follow up were censored from
the analysis at the time of their last follow up date.
Treatment related toxicity was assessed as a secondary
endpoint. Adverse events were graded according to the
National Cancer Institute Common Toxicity Criteria
grading system [36]. The incidence, severity, and causal
relation to treatment of these events were compared
between treatment groups. The study was conducted
according to globally accepted standards of Good Clini-
cal Practice and in agreement with the declaration of
Helsinki and was approved by the Institutional Review
Board (IRB). All patients have signed an informed con-
sent form before their enrollement into the study.
Results
Thirty one consecutive patients met the eligibility cri-
teria and were enrolled; 16 patients were randomized to
the cisplatin arm (group I) and 15 to the paclitaxel arm
(group II). The patients’ demographic characteristics are
listed in table 1. Age, parity, histology, presence of
hydronephrosis, and lymph node involvement were not
different in both groups. Only median tumor size was
slightly larger for group II patients (6 cm) compared to
that of group I patients (4.75 cm), but this was not sta-
tistically significant (p = 0.16).
Treatment details are listed in table 2. The mean
number of chemotherapy cycles was comparable [4.6 ±
0.9 vs. 4.3 ± 1.3], with 87% and 80% of patients receiv-
ing ≥4 doses in groups I and II, respectively. The med-
ian dose to point A was slightly higher for group I
patients (74 vs 66 Gy, p = 0.27). This is due to the fact
that more patients in group IIw e r ee n r o l l e da sp e l v i c
recurrences after surgery and received an external beam
radiation boost instead of uterovaginal brachytherapy. In
group I, only 3 patients (19%) did not receive UVB com-
pared to 6 patients (40%) in group II (p = 0.84). The
mean duration of radiation therapy was similar in both
groups (53.1 ± 9.9 vs. 55.8 ± 9.0 days; p = 0.56). Treat-
ment related acute toxicity is listed in table 3. Both
groups had comparable hematological toxicity, but more
patients in group II had severe diarrhea (53% vs. 37%),
and severe allergic reactions (40% vs. 6%). In two group
II patients, chemotherapy had to be discontinued
because of drug-related severe allergic reactions. Also,
delay in chemotherapy was more common with group II
than with group I patients (47% vs. 25%), but this differ-
ence was not statistically significant (p = 0.22).
There was a non-significant trend for more local and
distant failure in group II. Seven patients of group I
(44%) suffered tumor relapse [three locally and four out-
side the pelvis], while 8 group II patients (53%) devel-
oped tumor recurrence [three locally, two with distant
metastasis, and three locally and distantly]. At 2 years,
local control rates were 93% for group I and 70% for
group II (p = ns).
Figure 1 shows progression free survival with no dif-
ference for both groups. The Median survival time was
Table 1 Patient characteristics. Group I received
concurrent cisplatin and group II received concurrent
paclitaxel
Group I Group II
Number of patients 16 * 15 *
Median age (years) 56 (37-71) * 48 (38-80) *
Parity 4 (0-11) * 5 (2-9) *
Squamous cell pathology 13 (81%) * 14 (93%) *
Stage III-IVA 7 (44%) * 8(53%) *
Median Tumor size (cm) 4.75 (2.5-8) * 6 (3-11) *
Hydronephrosis 3 (19%) * 5 (33%) *
Positive pelvic lymph nodes 3 (19%) * 5 (33%) *
Enrolled as pelvic recurrence 2 (13%) * 5 (33%) *
* Shown in parentheses, are range or percentage values as applicable.
Table 2 Chemotherapy and radiation therapy treatment
parameters
Group I Group II
Chemotherapy cycles 5 (3-6) * 5 (1-6) *
>4 cycles 14 (87%) * 12 (80%) *
EBRT dose 40 (40-66) * 40 (40-66) *
Dose to point A 33 (5-52) * 34 (0-58) *
No UV brachytherapy 3 (19%) * 6 (40%) *
Total dose to point A 75 (60-93) * 66 (40-98) *
Group I received concurrent cisplatin and group II received concurrent
paclitaxel.
* Numbers represent number of patients with percentages when indicated, or
median values with ranges (shown in parentheses).
EBRT = external beam radiotherapy; UV=uterovaginal
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(Figure 2). At the end of the study 54% of group I vs.
42% of group II patients were still alive. The proportion
of patients surviving at 2 and 5 years was 78% and 54%
for group I vs. 73% and 42% for group II respectively (p
= 0.651).
Several treatment and patient related factors were
assessed for their prognostic significance. These
included age, number of chemotherapy cycles, disease
stage, presence of hydronephrosis, tumor size, delay in
chemotherapy, radiation dose to point A, and the use of
uterovaginal brachytherapy. None of these factors was
found to have significant influence on disease free or
overall survival (table 4).
Discussion
This small phase II study provides a direct comparison
between cisplatin and paclitaxel used as weekly concur-
rent chemotherapy with definitive radiation for
advanced carcinoma of the cervix. Our data indicate
that the overall response and progression free survival
rates with the use of paclitaxel, which is the experimen-
tal arm, are not superior to those with cisplatin. In fact,
there were non-significant trends for a higher relapse
rate, higher gastrointestinal toxicity, and more allergic
reactions in the concurrent paclitaxel group. Taken
together, these results indicate that paclitaxel does not
provide any clinical advantage over the current standard
of concurrent cisplatin in CTRT for patients with
advanced cervical carcinoma.
Although many prospective studies had shown that
CTRT with cisplatin-based chemotherapy clearly
improve the outcome of patients with carcinoma of the
cervix, many patients treated on these protocols con-
tinue to fail in the pelvis and at distant sites
[6,16,22,23]. In addition, one intergroup study using
weekly concurrent cisplatin with radiotherapy for
patients with carcinoma of the cervix could not demon-
strate a beneficial effect of CTRT over standard RT
Table 3 Incidence and types of acute toxicity
Toxicity endpoint Group I Group II
Leucopenia (grade 1-4) 3 (19%) 4 (27%)
All hematologic (grade 3-4) 2 (12%) 1 (7%)
Neurologic (grade I) 2 (12%) 0
Diarrhea (grade 3-4) 6 (37%) 8 (53%)
Allergic reactions 1 (6%) 6 (40%)
Delay in CT 4 (25%) 7 (47%)
Group I received concurrent cisplatin and group II received concurrent
paclitaxel. Two patients in group II had to discontinue treatment in cycles 1 &
2 because of severe allergic reactions.
One patient in group I developed an allergic reaction to metochlorpropramide
given as antiemetic.
Figure 1 Kaplan-Meier analysis of progression free survival per
treatment group.
Figure 2 Kaplan-Meier analysis of Overall survival per
treatment group.
Table 4 Univariate analysis of several patient, tumor, and
treatment parameters
Factor p-value
Age 0.29
Number of chemotherapy cycles 0.06
Stage 0.75
Hydronephrosis 0.93
Tumor size 0.16
Delay in Chemotherapy 0.22
Dose to Point A 0.27
HDR brachytherapy 0.84
Only the number of chemotherapy cycles was borderline significant.
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to many factors like possible enrollment of patients with
paraaortic lymph nodes, and an imbalance among ran-
domization groups for known prognostic factors such as
anemia [22,37]. These facts have lead many groups to
investigate other drugs for CTRT like paclitaxel in an
attempt to improve on what can be achieved by concur-
rent cisplatin [31,38-44]. In all these studies paclitaxel
was used in conjunction with either cisplatin (4/7 stu-
dies) or carboplatin (3/7 studies) but was never used
alone for CTRT. The majority of these studies was
p h a s eI( 4 / 7s t u d i e s ) ,w i t ho n es t u d yb e i n gac o m b i n e d
phase I/II study conducted by the GOG [42]. The num-
ber of patients enrolled in these studies varied between
8 and 35 patients and the rates of progression free survi-
val ranged between 39 and 88%. The dose limiting toxi-
city was primarily neutropenia in 4 studies [38,41,42,44]
or diarrhea [31,39,40]. In our phase II study reported
here, we enrolled 31 patients and progression free survi-
val was 61% for the cisplatin arm and 63% for the pacli-
taxel arm with severe grade III diarrhea being the most
common toxicity (37% and 54% for the cisplatin and
paclitaxel groups, respectively). These data are in agree-
ment with what other groups have reported and do not
suggest that paclitaxel provides any advantage in out-
come or toxicity over the current standard using cispla-
tin. This finding is in line with what was found in a
larger study by the GOG which also compared concur-
rent single agent CTRT consisting of either weekly cis-
platin or protracted 5-fluorouracil (5-Fu) infusion. The
results of that study showed no superiority of the
experimental 5-Fu arm and the study was prematurely
closed [45].
There are many studies that investigated other experi-
mental protocols for concurrent CTRT in advanced car-
cinoma of the cervix using various chemotherapy
regimens such as 5-Fu, epirubicin, 5-Fu with mitomycin
C, hydroxyurea, gemcitabine, carboplatin, tirapazamine,
topotecan, or vinorelbine [46-64]. Few of these drugs
were tested in randomized trials like 5-Fu, epirubicin,
hydroxyurea, mitomycin and gemcitabine, as single
agents or in combination [46-48,53]. Others have only
been tested in phase I/II studies and some of them have
shown promising results. Perhaps the most promising
and most studied drugs of this group are gemcitabine,
tirapazamine, and topotecan. In a phase II randomized
study by Dueñas-Gonzalez et al, patients with stage IB2-
IIB disease were randomized to cisplatin or cisplatin plus
gemcitabine and concurrent radiation therapy, followed
by radical hysterectomy 4 weeks later. The complete
pathologic response rate was higher in the cisplatin plus
gemcitabine arm compared to the cisplatin alone arm
(75% vs. 55%, respectively; p = 0.02), but gastrointestinal
and hematologic toxicities were significantly lower in the
cisplatin-alone arm [53]. A phase III randomized trial
testing this combination for definitive CTRT in stages IIB
to IVA disease, has completed accrual but results are not
yet available. Similarly, encouraging results have been
obtained in phase I studies using cisplatin-combination
CTRT with either topotecan or tirapazamine [60-62].
Several phase I/II studies are currently investigating the
combination cisplatin-topotecan and GOG trial 0219 is
testing the added value of tirapazamine to cisplatin for
CTRT in carcinoma of the cervix.
T h er a t eo fg a s t r o i n t e s t i n a l( G I )t o x i c i t yi no u rs t u d y
manifesting as severe diarrh e a ,w a sh i g hi nb o t ha r m s
although slightly higher in the paclitaxel arm. In addi-
tion there were more severe allergic reactions in the
paclitaxel arm and in 2 patients, chemotherapy had to
be discontinued due to the severity of these allergic
reactions, and in general, more chemotherapy delays
were encountered in this group. It is difficult to com-
pare this toxicity pattern with other studies from the lit-
erature, because none of these studies used either
paclitaxel or cisplatin alone for CTRT, instead they used
both drugs in combination with various dose-adminis-
tration schedules. However, one could note that in at
least 3 of the phase I studies that included paclitaxel,
severe diarrhea was the limiting toxicity which agrees
with our findings [31,39,40]. It is of concern that this
difference in toxicity between our treatment groups with
the disruption and delays in chemotherapy delivery in
group II, could have negatively affected this group’s out-
come. This is particularly important because this group
was also at a relative disadvantage regarding tumor bulk
(larger median tumor size) and a smaller number of
those patients could benefit from UV brachytherapy (9/
15 vs. 13/16 for group I) due to anatomical constraints.
However, because of the small size of the study it was
not possible to fully evaluate the influence of these fac-
tors either separately or all combined.
A total of 10 patients (32%) from both treatment
groups developed systemic metastases, a rate consistent
with what is reported in the literature, and which
emphasizes that the risk of distant recurrence remains a
major concern for these high risk patients. Taken as
individual studies, data from the various CTRT trials
have not consistently shown a reduction in distant
metastases (DM) in patients receiving systemic che-
motherapy when it was primarily given as a radiosensiti-
zer [6-16,23,24]. However, when these data were
analyzed together, two metaanalyses found a positive
effect of concurrent CTRT on distant recurrence
[65,66]. Among the studies that used platinum-based
chemotherapy, only the radiation therapy and oncology
g r o u p( R T O G )9 0 - 0 1s t u d ys h o w e das i g n i f i c a n te f f e c t
of CT on the reduction of DM at both 5 and 8 years of
follow-up [7,23]. It is of interest to note, that in that
Geara et al. Radiation Oncology 2010, 5:84
http://www.ro-journal.com/content/5/1/84
Page 5 of 8study, chemotherapy was given as full cycles of cisplatin
and 5-Fu during the course of RT, and the dose of cis-
platin was highest compared to what was used in the
other studies (75 mg/m
2 vs. 60, 50, or 40 mg/m
2).
Among the studies with noncisplatin-based chemother-
apy, only the study reported by Wong et al. showed a
significant impact on DM [14]. In that trial, CT con-
sisted of epirubicin as a single agent for concurrent
CTRT followed by adjuvant therapy with the same drug
for 5 cycles. It remains unclear what are the key factors
that made the experimental arm in these two particular
studies effective against DM. One could speculate that
the delivery of full cycle and higher doses of chemother-
apy, and/or the use of planned adjuvant chemotherapy
could, in theory, better address the risk of systemic
recurrence. However, this remains speculative until it is
demonstrated in controlledr a n d o m i z e ds t u d i e s ,a n d
unfortunately, to our knowledge, there are no such stu-
dies currently in progress. The only available informa-
tion comes from retrospective studies and there are
some which critically examined this question and
reported similar findings. In a single institution study,
Kim et al. reported a comparison between 2 well
balanced groups of patients with stage IB-II carcinoma
of the cervix who were treated by concurrent CTRT
with or without 3 additional cycles of adjuvant platinum
(cisplatin or carboplatin)-5Fu chemotherapy [67]. The
authors found no effect of adjuvant chemotherapy on
the incidence of distant metastases or distant nodal
relapses. They also found that adjuvant chemotherapy
was relatively difficult to complete, with only 63% of the
patients receiving all 3 cycles, and those in the adjuvant
group experienced a higher rate of late grade III-IV rec-
tal complications. Similar results were published by Lee
et al. on patients receiving adjuvant CTRT after radical
hysterectomy and treated either by 3 additional cycles of
cisplatin-5Fu or no additional therapy [68]. Although
these two studies are not prospective or randomized
trials, they still indicate that the routine use of adjuvant
cisplatin-based chemotherapy may not be the best
approach to address the risk of distant relapse in this
patient population.
In summary, these data show that concurrent chemor-
adiation for advanced cervical cancer using weekly pacli-
taxel was not superior to concurrent cisplatin and was
possibly associated with more severe gastrointestinal
toxicity and more allergic reactions. Progression free
survival was equivalent with both drugs and failure at
distant sites remains high in both groups, which may
indicate the need for additional effective therapy.
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